Literature DB >> 4094443

Hydergine pharmacokinetics in the elderly.

D Lavène, H Humbert, J R Kiechel, C Ducreuzet, D Lajoie, L Guillevin.   

Abstract

The pharmacokinetics of Hydergine was studied following intramuscular administration in a group of 6 subjects aged 76-86 and following oral administration in 6 subjects aged 66-86. Comparison with a control group of healthy volunteers (average age of 25) showed: --a marked reduction (- 50%) in renal clearance (p less than 0.001), related to the decrease in creatinine clearance in this population; --a lowering (- 30%) in metabolic clearance (p less than 0.02) in elderly subjects probably related to the decrease in hepatic blood flow observed with age; --a marked increase in bioavailability (X 2.5) following oral administration in elderly subjects, due either to increased absorption, or to a decreased hepatic first-pass effect. These results underline the value of studying the kinetics of geriatric drugs in the target population.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4094443

Source DB:  PubMed          Journal:  J Pharmacol        ISSN: 0021-793X


  4 in total

1.  Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function.

Authors:  W Kirch; A Nokhodian; A Halabi; G Weidinger
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1992 Jan-Mar       Impact factor: 2.441

Review 2.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 3.  Co-dergocrine mesylate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in age-related cognitive decline.

Authors:  A N Wadworth; P Chrisp
Journal:  Drugs Aging       Date:  1992 May-Jun       Impact factor: 3.923

4.  The absolute systemic availability of a new oral formulation of co-dergocrine in healthy subjects.

Authors:  P Dominiak; J Grevel; E Abisch; H Grobecker; H J Dennler; D Welzel
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.